Editorial Team
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Editorial Team | Published : October 18, 2012 10:59 AM IST
Pharma major Lupin announced on Wednesday that its subsidiary, Lupin Pharmaceuticals, has received final approval for its Irbesartan tablets from the US Food and Drugs Administration (FDA). It can now market a generic version of Sanofi Aventis's Avapro tablets. Irbesartan tablets are used for treating hypertension and nephropathy in type 2 diabetic patients and are available in 75 mg, 150 mg and 300 mg strength.
According to the IMS health sales data, Avapro tablets had annual US sales of about $400.7 million in June. With 5.1% market share by prescriptions, Lupin is the fifth largest generic player in the US. It is also one among the top 10 fastest growing pharma player in India, Japan and South Africa, the company said.
Disclaimer: The content on TheHealthSite.com is only for informational purposes. It is not at all professional medical advice. Always consult your doctor or a healthcare specialist for any questions regarding your health or a medical condition.